Trial Profile
Retrospective study of the utility of TAS-102 as a third-line chemotherapy in the patients with metastatic colorectal cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary) ; Irinotecan; Panitumumab
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2018 New trial record
- 01 Apr 2018 Results published in the Anticancer Research.